Participants will continue taking New Hormonal Agents (NHA) while receiving sipuleucel-t as standard of care.
1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily
Drug: Enzalutamide
160 mg of Enzalutamide will be given orally daily ending at week 4
Other Name: Xtandi
Drug: Apalutamide
240 mg of Apalutamide will be given orally daily ending at week 4
Drug: Sipuleucel-T
Sipuleucel-T is considered standard of care and will be infused into the participant three times at approximately 2-week intervals starting week 0, 2 and 4.
Other Name: Provenge
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
